SCHEMBL1105447

SCHEMBL1105447

Cc1ccc(-c2nc3ccccc3s2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 7/20 0.69
RAB9A P51151 6/20 0.69
KDM4E B2RXH2 5/20 0.69
NPC1 O15118 5/20 0.69
GLA P06280 3/20 0.69
GAA P10253 3/20 0.69
MAPT P10636 3/20 0.69
ALDH1A1 P00352 2/20 0.69
MMP9 P14780 2/20 0.69
MMP8 P22894 2/20 0.69
LMNA P02545 1/20 0.69
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
L3MBTL1 Q9Y468 2/20 0.68
PKM P14618 1/20 0.68
PAX8 Q06710 1/20 0.68
NOD2 Q9HC29 1/20 0.68
TNF P01375 1/20 0.68
NOD1 Q9Y239 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13853327 0.92 APP (0.73) APPRAB9AKDM4ENPC1GLA
SCHEMBL10023313 0.91 APP (0.58) APPRAB9AKDM4ENPC1GLA
SCHEMBL366824 0.90 RAB9A (0.81) APPRAB9AKDM4ENPC1GLA
SCHEMBL29474819 0.90 RAB9A (0.81) APPRAB9AKDM4ENPC1GLA
SCHEMBL10047622 0.89 APP (0.68) APPRAB9AKDM4ENPC1GLA
SCHEMBL14195515 0.89 APP (0.68) APPRAB9AKDM4ENPC1GLA
SCHEMBL16998716 0.89 RAB9A (0.68) APPRAB9AKDM4ENPC1GLA
SCHEMBL24295138 0.88 RAB9A (0.79) APPRAB9AKDM4ENPC1GLA
SCHEMBL17059020 0.87 KDM4E (0.64) APPRAB9AKDM4ENPC1GLA
SCHEMBL15786286 0.87 KDM4E (0.64) APPRAB9AKDM4ENPC1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118725333-A Keggin type polyacid-based metal organic framework molecular material, synthesis method and application of Keggin type polyacid-based metal organic framework molecular material as photocatalyst 周口师范学院 2024-10-01 CN claimed
CN-119913222-A Method for continuously preparing benzenesulfonic acid compound by electrochemical-enzymatic coupling 南京工业大学 2025-05-02 CN disclosed
CN-118725333-A Keggin type polyacid-based metal organic framework molecular material, synthesis method and application of Keggin type polyacid-based metal organic framework molecular material as photocatalyst 周口师范学院 2024-10-01 CN disclosed
CN-116422347-B Preparation method and application of QDs/TNTs composite catalyst material 浙江理工大学 2024-09-13 CN disclosed
CN-118047723-A Process for preparing benzoazacyclic compounds 常州大学 2024-05-17 CN disclosed
CN-115197165-B Method for preparing benzothiazole compound by reacting photocatalytic toluene compound and o-aminophenylsulfiol 河南师范大学 2024-01-26 CN disclosed
US-11718606-B2 Polycyclic compound and organic light emitting element comprising same LG CHEM, LTD. (KR) 2023-08-08 US disclosed
CN-116422347-A Preparation method and application of QDs/TNTs composite catalyst material 浙江理工大学 2023-07-14 CN disclosed
US-20230010258-A1 COMPOSITION FOR PREVENTING OR INHIBITING AXONAL DEGENERATION CHECKMATE THERAPEUTICS INC. (KR) 2023-01-12 US disclosed
CN-111793040-B Preparation method of 2-substituted benzothiazole 太原理工大学 2023-01-03 CN disclosed
EP-1473286-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-03 EP disclosed
EP-0235345-B1 INDENE COMPOUNDS Taiyo Pharmaceutical Industry Co., Ltd. (JP) 1992-10-14 EP disclosed
US-4876345-A VASODILATORS, CALCIUM ANTAGONISTS; ANGINA PECTORIS TAIYO PHARMACEUTICAL INDUSTRY CO., LTD. (JP) 1989-10-24 US disclosed
US-4762927-A ANGINA PECTORIS TAIYO PHARMACEUTICAL INDUSTRY CO., LTD. (JP) 1988-08-09 US disclosed
EP-0235345-A1 Indene compounds Taiyo Pharmaceutical Industry Co., Ltd. (JP) 1987-09-09 EP disclosed
EP-0010120-B1 1-(BENZOTHIAZOL-2-YL)-4-DIALKOXYPHOSPHINYL METHYLBENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM KANEBO, LTD. (JP) 1983-03-02 EP disclosed
US-4232010-A CARDIOTONIC AND HYPOTENSIVE AGENTS KANEBO, LTD. (JP) 1980-11-04 US disclosed
EP-0010120-A1 1-(benzothiazol-2-yl)-4-dialkoxyphosphinyl methylbenzene derivatives and pharmaceutical compositions containing them KANEBO, LTD. (JP) 1980-04-30 EP disclosed
US-3962056-A MOLDING, COATING EASTMAN KODAK COMPANY (US) 1976-06-08 US disclosed
US-3962055-A MOLDING, COATING EASTMAN KODAK COMPANY (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718606-B2 Polycyclic compound and organic light emitting element comprising same CRY1, CRY2, CYP1A1 APP 745/4885RAB9A 3043/4885KDM4E 3435/4885
US-20230010258-A1 COMPOSITION FOR PREVENTING OR INHIBITING AXONAL DEGENERATION BDNF, GAP43, PRPH APP 63/4885RAB9A 2111/4885KDM4E 4503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.